A Guide to Diabetes and CGM Device Sales
Continuous glucose monitoring is racing toward $29 billion by 2030. The leading diabetes and CGM companies, what the selling is like, and what reps should watch.
*Publishing note for launch: every company name below (shown in bold) should link to its Vocari platform company page.*
Few categories in medical devices are growing like continuous glucose monitoring. The global CGM market ran about $13.5 billion in 2025 and is projected to reach nearly $29 billion by 2030, growth of more than 16 percent a year, as sensors move from a diabetes tool toward mainstream metabolic health.
That momentum makes diabetes and CGM one of the most active hiring grounds in the industry. Here is who leads it, and what the selling is like.
How big is the CGM market?
Continuous glucose monitoring is on track to roughly double, from about $13.5 billion in 2025 to nearly $29 billion by 2030, growing more than 16 percent a year. Roughly 10 million people worldwide already use prescription CGM from the two market leaders, and over-the-counter sensors are opening the category to people without diabetes.
That combination of a large installed base and a still-expanding market is what makes CGM one of the highest-momentum spaces in devices.
Who are the leading CGM and diabetes companies?
A few companies define the category:
- Abbott is the global CGM leader, with its FreeStyle Libre franchise holding roughly 58 percent of the worldwide market on about $7.6 billion in CGM sales. Libre is one of the most successful device franchises in the industry.
- Dexcom is the close specialist challenger, a roughly $4.7 billion pure-play that leads the US market on its G7 sensor and has moved into over-the-counter with the Stelo biosensor.
- MiniMed, spun out of Medtronic in 2026, is the roughly $3 billion insulin-pump and automated-delivery leader, pairing the MiniMed 780G system with its own CGM sensors for more than 640,000 pump users.
Smaller innovators like Senseonics, maker of the long-term implantable Eversense sensor, round out a category still open to new approaches.
What is diabetes and CGM sales like?
It is a different rhythm from the operating room. Diabetes and CGM selling leans toward endocrinology and primary-care offices, pharmacies, and payers, with a high-frequency, high-volume feel rather than the case-by-case intensity of surgical device sales.
Because sensors are consumables worn continuously, the business rewards driving adoption and adherence across large patient populations. For reps who prefer building broad prescriber relationships over scrubbing into surgeries, it is an appealing lane.
Is CGM sales a good career bet?
The growth is real and durable, which tends to mean expanding teams and new territories. The category's move into over-the-counter and metabolic health could widen the customer base well beyond diabetes.
One thing to watch is reimbursement. US Medicare is moving CGMs into competitive bidding, with pricing pressure expected from 2028, which could affect margins and, over time, comp. It is a healthy market with a long runway, but a smart rep keeps an eye on the payer landscape.
Key Takeaways
- The global CGM market is projected to nearly double to about $29 billion by 2030, growing over 16 percent a year.
- Abbott leads globally with FreeStyle Libre (about 58 percent share); Dexcom leads the US market.
- MiniMed, spun out of Medtronic in 2026, leads insulin pumps and automated delivery.
- CGM selling is high-frequency, prescriber- and payer-focused, unlike case-by-case surgical sales.
- Watch reimbursement: US Medicare competitive bidding brings CGM pricing pressure from 2028.
Frequently Asked Questions
How big is the CGM market?
The global continuous glucose monitoring market ran about $13.5 billion in 2025 and is projected to reach nearly $29 billion by 2030, growth of more than 16 percent a year. Roughly 10 million people worldwide already use prescription CGM, and over-the-counter sensors are expanding the category further.
Who are the biggest CGM companies?
Abbott leads globally with its FreeStyle Libre franchise, holding roughly 58 percent of the market on about $7.6 billion in CGM sales. Dexcom is the specialist challenger and US leader at about $4.7 billion, and MiniMed leads insulin pumps and automated insulin delivery. Senseonics offers a long-term implantable sensor.
What is diabetes device sales like?
It is high-frequency, high-volume selling focused on endocrinology and primary-care offices, pharmacies, and payers, rather than the case-by-case intensity of the operating room. Because CGM sensors are worn continuously as consumables, the work centers on driving adoption and adherence across large patient populations.
Is CGM a good field for sales reps?
It is one of the highest-growth areas in devices, which tends to mean expanding teams and new territories, and the shift toward over-the-counter and metabolic health could widen the market further. The main thing to watch is reimbursement, since US Medicare competitive bidding is expected to pressure CGM pricing from 2028.
Related Reading
- The Medical Device Companies Every New Rep Should Know
- The 2026 Medical Sales Salary Guide
- The Top Cardiovascular Device Companies
About This Series
This guide is part of Vocari Intelligence, The Lobby’s series on how the medical sales business actually works, built from company financials and market data.
Drawn to diabetes and CGM? Set your parameters once on [Vocari](https://www.myvocari.com) and let matching roles come to you.